Mediagene de TNL sube un 2128,57% mientras que la posibilidad de eliminación de la lista de Nasdaq se acerca y se implementa una división inversa

The share price rose to its highest level so far this month today, with an intraday gain of 2128.57%.

TNL Mediagene faces imminent Nasdaq delisting risks after failing to meet the $1 bid price rule. A conditional extension until January 7, 2026, was granted following a December 16 hearing, contingent on compliance. The company announced a reverse share split on December 19 to address the issue, a move often seen as a last-ditch effort to inflate share prices but one that erodes investor trust. The delisting threat has amplified volatility, with the stock’s survival on the exchange now hinging on its ability to stabilize demand ahead of the deadline.

Financial fundamentals remain dire, with a trailing twelve months net profit margin of -167.88% and a 18.3% quarterly revenue decline to $21.79. A recent “Buy” rating from Benchmark, though outdated, contrasts with the company’s weak return on investment of -164.59%, signaling poor capital allocation. Despite the analyst’s price target of $3.50, the stock’s high leverage (58.06% debt-to-equity) and lack of dividend history underscore its speculative nature. Regulatory uncertainty and operational challenges, including no visible turnaround strategy, leave investors with limited confidence in long-term recovery.